Is BPC-157 Legal? What US Law and WADA Say in 2026

BPC-157 is not approved by the FDA for any use, so it cannot lawfully be sold as a drug for people, but it is not a controlled substance, and the enforcement actions we reviewed in 2026 were brought against sellers rather than buyers. Its compounding status is unsettled: an FDA advisory committee recommended it for the 503A bulks list in July 2026, no rule has followed, and a separate interim access policy is under White House review. In sport it is prohibited at all times.

This is general information about federal law, not legal advice, and it does not cover state law.

Is BPC-157 FDA-approved?

No. No application for a BPC-157 drug has been approved. When FDA staff reviewed it for the July 2026 advisory meeting, they identified five published human reports, most of them meeting abstracts or small single-clinic series, and concluded that there was insufficient clinical safety information to characterize the compound and inadequate data to support effectiveness for the use proposed, ulcerative colitis. Our side-by-side with TB-500 walks through that record.

Approval matters for legality because of how federal drug law is built. Under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act, a product is a drug if it is intended to treat or prevent disease or to affect the structure or function of the body. Under section 505(a), a new drug may not be introduced into interstate commerce without an approved application. A BPC-157 product marketed for human use is, on the FDA's reading, an unapproved new drug.

The compounding question

Compounding is a separate route. A state-licensed pharmacy may prepare a medication for an individual patient with a prescription, using bulk ingredients that have a USP monograph, are components of an approved drug, or appear on the FDA's 503A bulks list. BPC-157 meets none of those conditions today. Its history since 2023 runs as follows.

2023. The FDA placed BPC-157 in Category 2 of its interim compounding policy, the category for substances that may present significant safety risks. The agency's safety summary cites risk of immunogenicity and limited safety information.
April 15, 2026. The FDA gave notice that it would remove 12 peptides, BPC-157 among them, from Category 2 because their nominators had withdrawn the nominations. They were not moved to Category 1, the category where the agency generally does not act against compounding while it evaluates a substance.
July 23, 2026. The Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend BPC-157 for the 503A bulks list. FDA staff had proposed against it. The vote is advisory, and we could find no proposed or final rule acting on it as of this writing.
October 14, 2026. The White House Office of Information and Regulatory Affairs received an FDA notice titled "Interim Access Policy for Compounding Using Certain Peptides." Its text is not public. The Associated Press reported, citing two unnamed sources, that BPC-157 would be covered and that the approach would be enforcement discretion. Neither the FDA nor HHS has confirmed that.

If that policy is issued and covers BPC-157, it would describe where the FDA does not intend to act against licensed pharmacies filling prescriptions. It would not approve BPC-157, and law firms reviewing the filing, including Holland & Knight, expect it to concern state-licensed 503A pharmacies rather than research-chemical sellers. Our coverage of the filing tracks what is confirmed.

Research use only labels

Most BPC-157 sold online carries a "research use only" label. That label describes a lawful arrangement for genuine laboratory supply, governed in part by 21 CFR 312.160, which sets conditions for shipping new drugs for laboratory and animal testing. It is not a blanket exemption.

The FDA judges intended use from the whole record. Its regulation on intended use, 21 CFR 201.128, says objective intent can be shown by labeling claims, advertising, statements and the circumstances of distribution. On August 24, 2026 the agency sent warning letters to five online peptide sellers. Each said that despite research-use statements, evidence from the website established that the products were intended for human use. Law firm ArentFox Schiff, reviewing all five, noted that the FDA pointed to disease claims, instructions, calculators and companion supplies. One letter treated descriptions phrased as research, such as "studied for" and "investigated for," as part of that evidence. Our coverage of those letters has the detail, and our field guide on what research use only means explains the category.

Buyer versus seller: the enforcement record

The published record points one way, with limits worth stating.

Sellers. The August 2026 warning letters went to sellers, under provisions about introducing unapproved new drugs into interstate commerce, and warned that uncorrected violations could lead to seizure and injunction. In a separate criminal case, a federal court in the Northern District of Indiana on July 30, 2026 sentenced the owner of an online business that sold peptides, hCG and SARMs to five years and ten months in prison, after a guilty plea.

Buyers. We found no federal enforcement action against an individual for buying BPC-157 for personal use in the sources we reviewed. Holland & Knight's October 2026 analysis likewise describes enforcement aimed at sellers. That describes where enforcement has gone, not a guarantee about any purchase.

Imports. The FDA states that in most circumstances it is illegal for individuals to import drugs into the United States for personal use. Material shipped from abroad is treated more strictly than a domestic purchase.

Controlled substances. BPC-157 is not scheduled under the Controlled Substances Act, and the 2026 actions in this market were brought under drug approval law. Our explainer on whether research peptides are legal covers the wider framework.

Sport: WADA S0

BPC-157 is prohibited at all times under section S0, non-approved substances, of the World Anti-Doping Agency's Prohibited List. S0 covers any pharmacological substance not addressed elsewhere on the list that has no current approval from any government health authority for human use, and the 2026 list names BPC-157 as an example. It was first named on the 2022 list. USADA describes it as an experimental peptide that the FDA has not approved for human use.

For athletes, that settles the practical question regardless of US compounding policy. A pharmacy listing or an interim access policy would not be a government approval for therapeutic use of the kind S0 refers to, and products marketed as supplements can contain it. Athletes should check with their own anti-doping organization before using any product.

Frequently asked questions

Is BPC-157 legal to buy in the US?

It is not a controlled substance, and the federal actions we reviewed targeted sellers. It is also not approved for human use, imports for personal use are generally illegal, and state law may differ. For a specific situation, ask a lawyer.

Is BPC-157 legal to sell?

Not as a drug for human use. The FDA treats a product intended for people as an unapproved new drug, and in 2026 it said research-use labels did not change that conclusion when the website showed human use.

Did the FDA approve BPC-157 in 2026?

No. An advisory committee recommended it for the compounding bulks list. That is not an approval, and no rule has been proposed.

Can a pharmacy compound BPC-157?

Not on the current record. It is not on the 503A bulks list and not in Category 1. An interim access policy that may cover it is under review, and its terms are not public.

Is BPC-157 banned in sport?

Yes. WADA prohibits it at all times under S0, where it has been named since the 2022 list.

Sources:

Nothing here is legal or medical advice, and nothing above is dosing guidance or a treatment claim. Research use only.

For research use only · Not for human or veterinary use · No research compound discussed here is FDA-approved for any indication